Magazine Article | November 8, 2017

Can We Make Innovative Medicines Affordable? Part 2

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

Concluding A Most Insightful Drug-Pricing Discussion – Part 2

In last month’s issue, we published “Can We Make Innovative Medicines Affordable? A Most Insightful Discussion On Drug Pricing — Part 1.” Developed from the Our Common Goal: Ensuring Access and Affordability of Innovative Medicines panel discussion at the 2017 BIO International Convention in San Diego, participants include an insurance industry executive (Steven Miller, M.D., SVP and chief medical officer at Express Scripts), three biopharmaceutical industry executives (Ron Cohen, M.D., CEO of Acorda Therapeutics [session moderator], Jeremy Levin, DPhil, MB, BChir, CEO of Ovid Therapeutics, and David Meeker, M.D., former EVP of Sanofi Genzyme) and one executive who spanned biopharma, retail pharmacy, drug distribution, and insurance (Jeffrey Berkowitz, formerly EVP at Merck, Walgreens Boots Alliance, and UnitedHealth Group). We pick up where we left off with Jeffrey Berkowitz responding to a question posed by David Meeker.

To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.